Patents Assigned to Sankyo Company Limited
-
Publication number: 20230058950Abstract: An object of the present invention is to provide a compound that has a specific chemical structure having an activation effect on SIRT6 and is useful as an active component for preventing and treating inflammatory diseases, and the present invention relates to a compound represented by Formula (1) or a pharmaceutically acceptable salt thereof, where each symbol in Formula (1) has the same definition as that described in the specification.Type: ApplicationFiled: January 23, 2020Publication date: February 23, 2023Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Junya KAWAI, Osamu IWAMOTO, Yuma UMEZAKI, Katsuyoshi NAKAJIMA, Hiroyuki TSURUOKA, Keiji SAITO, Nobuya KURIKAWA, Natsumi NISHIHAMA, Shinji TANAKA, Momoko OGITANI, Tomohiro HONDA, Wataru SAITOH, Tsuyoshi SONEDA, Nobuyuki OHKAWA
-
Patent number: 11583590Abstract: The present invention provides a novel antibody-pyrrolodiazepine derivative and a novel antibody-pyrrolodiazepine derivative conjugate using the same, and a novel CLDN6 and/or CLDN9 antibody.Type: GrantFiled: December 6, 2021Date of Patent: February 21, 2023Assignee: DAIICHI SANKYO COMPANY, LIMITEDInventors: Narihiro Toda, Yusuke Ota, Fuminao Doi, Masaki Meguro, Ichiro Hayakawa, Shinji Ashida, Takeshi Masuda, Takashi Nakada, Mitsuhiro Iwamoto, Naoya Harada, Tomoko Terauchi, Daisuke Okajima, Kensuke Nakamura, Hiroaki Uchida, Hirofumi Hamada
-
Patent number: 11584800Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety and has an excellent therapeutic effect, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER2 antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-(CH2)n2-C(?O)— wherein the anti-HER2 antibody is connected to the terminal L1, and the antitumor compound is connected to the carbonyl group of the —(CH2)n2-C(?O)— moiety with the nitrogen atom of the amino group at position 1 as the connecting position.Type: GrantFiled: August 19, 2020Date of Patent: February 21, 2023Assignee: DAIICHI SANKYO COMPANY, LIMITEDInventors: Hiroyuki Naito, Yusuke Ogitani, Takeshi Masuda, Takashi Nakada, Masao Yoshida, Shinji Ashida, Koji Morita, Hideki Miyazaki, Yuji Kasuya, Ichiro Hayakawa, Yuki Abe
-
Patent number: 11578138Abstract: The present invention provides a pharmaceutical composition comprising an antibody which binds specifically to human TLR7 or monkey TLR7 and does not bind to mouse TLR7 or rat TLR7, and has an activity of inhibiting a function of human TLR7 or monkey TLR7, and the like.Type: GrantFiled: July 2, 2021Date of Patent: February 14, 2023Assignees: Daiichi Sankyo Company, Limited, The University of TokyoInventors: Kensuke Miyake, Yusuke Murakami, Yuji Motoi, Atsuo Kanno, Toshiyuki Shimizu, Umeharu Ohto, Takaichi Shimozato, Atsushi Manno, Takashi Kagari, Jun Ishiguro, Kensuke Nakamura, Takashi Isobe
-
Publication number: 20230030720Abstract: The present invention provides a compound or a pharmaceutically acceptable salt thereof having an inhibitory action on the interaction between menin and an MLL protein. The compound represented by the formula (1) or a pharmaceutically acceptable salt thereof. wherein, in the formula (1), the dotted circle, R1, R2, R3, R4, R5, R6, R7, R8, Ring Q1, W, m and n are each as defined in the description.Type: ApplicationFiled: December 5, 2019Publication date: February 2, 2023Applicant: Daiichi Sankyo Company, LimitedInventors: Kenji Yoshikawa, Noriyasu Haginoya, Tomoaki Hamada, Ryutaro Kanada, Jun Watanabe, Yoshiko Kagoshima, Eri Tokumaru, Kenji Murata, Takayuki Baba, Mayumi Kitagawa, Akiko Kurimoto, Masashi Numata, Machiko Shiroishi, Taeko Shinozaki
-
Publication number: 20230025510Abstract: The present invention provides a novel compound or a pharmaceutically acceptable salt thereof having an inhibitory action on an EGFR tyrosine kinase having an exon 20 insertion mutation and/or a HER2 tyrosine kinase having an exon 20 insertion mutation, a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof wherein R1, R2, R3, R4, R5 and R6 in the Formula (I) are each as defined in the description.Type: ApplicationFiled: July 3, 2019Publication date: January 26, 2023Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Kenichi Yoshida, Kosuke Takeuchi, Hidekazu Inoue, Hideaki Kageji, Takayuki Momose, Keisuke Yoshida, Takeshi Jimbo, Akiko Egami
-
Patent number: 11555204Abstract: The present invention provides an approach to enhancing the production of a foreign protein serving as a protein-based pharmaceutical product in host cells such as cultured cells derived from a mammal. The present invention provides transformed cells having a novel Hspa5 gene promoter, and a method for secreting and producing a foreign protein at high levels using the transformed host cells.Type: GrantFiled: October 2, 2017Date of Patent: January 17, 2023Assignee: Daiichi Sankyo Company, LimitedInventors: Kenji Masuda, Koichi Nonaka, Hiroki Tanemura
-
Publication number: 20220411416Abstract: The present invention addresses the problem of providing a compound for prophylaxis and/or treatment of central inflammatory diseases, or a pharmacologically acceptable salt thereof. The present invention addresses a compound of a general formula (I) or a pharmacologically acceptable salt thereof as a means to solve the problem.Type: ApplicationFiled: June 21, 2022Publication date: December 29, 2022Applicant: Daiichi Sankyo Company, LimitedInventors: Keiji Saito, Katsuyoshi Nakajima, Yasuyuki Ogawa, Mitsuhiro Makino, Kaori Ito, Seiko Nagata, Makoto Hirasawa
-
Patent number: 11530211Abstract: It is an object of the present invention to provide a new compound capable of efficiently inducing differentiation from pluripotent stem cells into insulin-producing cells. The object of the present invention is achieved by a compound represented by formula (I): wherein R1, R2, R3, n and A have the same meanings as defined in the description, respectively, or a salt thereof.Type: GrantFiled: January 18, 2019Date of Patent: December 20, 2022Assignee: Daiichi Sankyo Company, LimitedInventors: Toshihiro Kiho, Tatsuya Yano, Satoshi Komoriya, Taisaku Tanaka
-
Publication number: 20220395579Abstract: The present invention provides a novel antibody-pyrrolodiazepine derivative and a novel antibody-pyrrolodiazepine derivative conjugate using the same, and a novel CLDN6 and/or CLDN9 antibody.Type: ApplicationFiled: June 26, 2022Publication date: December 15, 2022Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Narihiro TODA, Yusuke OTA, Fuminao DOI, Masaki MEGURO, Ichiro HAYAKAWA, Shinji ASHIDA, Takeshi MASUDA, Takashi NAKADA, Mitsuhiro IWAMOTO, Naoya HARADA, Tomoko TERAUCHI, Daisuke OKAJIMA, Kensuke NAKAMURA, Hiroaki UCHIDA, Hirofumi HAMADA
-
Publication number: 20220378920Abstract: The present invention provides a conjugate of an oligonucleotide having a nucleic acid sequence expected to have a pharmacological effect in hepatic parenchymal cells with a biantennary GalNAc unit, or a pharmaceutically acceptable salt thereof, and a medicament or the like containing the same as an active component.Type: ApplicationFiled: September 9, 2020Publication date: December 1, 2022Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Makoto Koizumi, Mitsuhiro Iwamoto, Yukiko Sekiguchi, Kentaro Ito
-
Patent number: 11512067Abstract: An object of the present invention is to provide a compound having an anti-inflammatory activity or a pharmacologically acceptable salt thereof. The solution of the present invention is a compound of general formula (1) or a pharmacologically acceptable salt thereof. wherein the symbols in the formula are defined below: A: e.g., Benzene, E: e.g., —CH2—, G: e.g., a 5-membered aromatic heterocyclic ring, X: e.g., cyclohexane, J: e.g., a 5-membered aromatic heterocyclic ring, Y: e.g., a phenyl group, R1, R2, R3: e.g., a halogen atom, R4: e.g., a C1-C6 alkyl group, R5: e.g., a hydrogen atom, R6a, R6b, R6c, R6d: e.g., a hydrogen atom, R7: e.g., a hydrogen atom, R8: e.g., a hydrogen atom, n1, n2, n3: e.g., 1.Type: GrantFiled: September 13, 2018Date of Patent: November 29, 2022Assignee: Daiichi Sankyo Company, LimitedInventors: Toru Taniguchi, Osamu Iwamoto, Keiji Saito, Katsuyoshi Nakajima, Yasuyuki Ogawa, Nobuya Kurikawa, Seiko Nagata, Kaori Ito, Eriko Kioi
-
Publication number: 20220372076Abstract: Disclosed are compositions and method related to variants of SPINK2 that bind to targets other than an endogenous target of SPINK2. In one embodiment, a peptide is provided that comprises the amino acid sequence SEQ ID NO: 1. In further embodiments, an amino acid sequences encoded by nucleotide positions 4 to 42 and/or nucleotide positions 94 to 189 in the nucleotide sequence of SEQ ID NO: 14 flank the amino terminus and the carboxyl terminus, respectively, of the amino acid sequence. In another embodiment, a peptide is provided that comprises an amino acid sequence derived from the amino acid sequence of SEQ ID NO: 1 in which a conservative substitution, deletion, addition and/or insertion of 1 to 5 (inclusive) amino acids has occurred at amino acids other than the 1st Xaa to the 12th Xaa counting from the amino terminus.Type: ApplicationFiled: May 2, 2022Publication date: November 24, 2022Applicant: Daiichi Sankyo Company, LimitedInventors: Daisuke Nishimiya, Ryuji Hashimoto
-
Publication number: 20220372440Abstract: The present invention aims to solve a problem in T-cell transfer therapy and the like, which is T-cell exhaustion, and to provide a technique to enhance T cell activity. T cells having cell surface markers of CD45RA+ and CCR7+ can be produced by culturing activated T cells in the presence of (a) a conditioned medium derived from stromal cells or (b) CXCL12.Type: ApplicationFiled: October 27, 2020Publication date: November 24, 2022Applicants: DAIICHI SANKYO COMPANY, LIMITED, KEIO UNIVERSITYInventors: Wataru Tomisato, Akihiko Yoshimura, Taisuke Kondo, Makoto Ando
-
Publication number: 20220364086Abstract: The present invention aims at establishing a novel therapy for facioscapulohumeral muscular dystrophy. An oligonucleotide or a pharmaceutically acceptable salt thereof, wherein the oligonucleotide comprises an oligonucleotide of 15-30 bases consisting of a nucleotide sequence complementary to the region of nucleotide Nos. 502-556 or 578-612 of DUX4-fl mRNA consisting of the nucleotide sequence as shown in SEQ ID NO: 1; the 5? and/or 3? end of the oligonucleotide may be chemically modified; and the oligonucleotide is capable of switching the splice form of the DUX4 gene from DUX4-fl to DUX4-s. A pharmaceutical drug comprising the above oligonucleotide or a pharmaceutically acceptable salt thereof (e.g. therapeutic for facioscapulohumeral muscular dystrophy).Type: ApplicationFiled: July 10, 2020Publication date: November 17, 2022Applicants: DAIICHI SANKYO COMPANY, LIMITED, Tokai University Educational SystemInventors: Makoto KOIZUMI, Akifumi NAKAMURA, Takahiro KATAGIRI, Hiroaki MITSUHASHI
-
Patent number: 11497741Abstract: Provision of a granular preparation that contains edoxaban or a pharmacologically acceptable salt thereof, and has the property of being rapidly dissolved or suspended by the addition of water. A granular preparation comprising first granules containing (A) edoxaban or a pharmacologically acceptable salt thereof, (B) a sugar alcohol, and (C) a water-swelling additive, and second granules containing (D) 0.5 to 10% by weight of carmellose sodium with respect to the total weight of the preparation, and (E) 70 to 90% by weight of xylitol or sorbitol with respect to the total weight of the preparation.Type: GrantFiled: June 26, 2019Date of Patent: November 15, 2022Assignee: DAIICHI SANKYO COMPANY, LIMITEDInventors: Wolfgang Schmid, Maren Kuhli, Christoph Schuh
-
Publication number: 20220339260Abstract: As an approach of efficiently inducing differentiation from pluripotent stem cells into insulin-producing cells, provided is a method comprising the step of three-dimensionally culturing cells in a medium containing a dihydroindolizinone derivative.Type: ApplicationFiled: July 7, 2020Publication date: October 27, 2022Applicants: TOKYO INSTITUTE OF TECHNOLOGY, DAIICHI SANKYO COMPANY, LIMITEDInventors: Shoen Kume, Nobuaki Shiraki, Tatsuya Yano, Toshihiro Kiho
-
Patent number: 11472784Abstract: An object of the present invention is to provide a compound having an anti-inflammatory activity or a pharmacologically acceptable salt thereof. The solution of the present invention is a compound of general formula (1) or a pharmacologically acceptable salt thereof. wherein the symbols in the formula are defined below: R1: e.g., a C1-C6 alkyl group; R2: a C1-C6 alkyl group; A: e.g., an oxygen atom; and R3: e.g., a C1-C6 alkyl group.Type: GrantFiled: March 25, 2021Date of Patent: October 18, 2022Assignee: Daiichi Sankyo Company, LimitedInventors: Keiji Saito, Katsuyoshi Nakajima, Toru Taniguchi, Osamu Iwamoto, Satoshi Shibuya, Yasuyuki Ogawa, Kazumasa Aoki, Nobuya Kurikawa, Shinji Tanaka, Momoko Ogitani, Eriko Kioi, Kaori Ito, Natsumi Nishihama, Tsuyoshi Mikkaichi, Wataru Saitoh
-
Patent number: 11459387Abstract: An object of the present invention is to provide a novel anti-CD147 antibody exhibiting potent antitumor efficacy and having excellent safety. Another object of the present invention is to provide a pharmaceutical product comprising such an antibody. Another object of the present invention is to provide a method for treating tumors using the antibody or the pharmaceutical product, for example. The present invention provides a CD147-specific antibody that activates CD147 and exhibits high antitumor efficacy. The present invention provides the anti-CD147 antibody that exhibits high antitumor efficacy independent of effector functions. The present invention provides a pharmaceutical composition comprising such an anti-CD147 antibody. The present invention provides a method for treating tumors using such an anti-CD147 antibody and/or pharmaceutical composition.Type: GrantFiled: October 12, 2021Date of Patent: October 4, 2022Assignee: DAIICHI SANKYO COMPANY, LIMITEDInventors: Keisuke Fukuchi, Kayoko Nanai, Masato Amano, Kozo Yoneda, Yusuke Totoki, Shoji Yamamoto
-
Publication number: 20220306725Abstract: SPINK2 mutant peptide conjugates are provided that inhibit KLK5. The KLK5 inhibitory peptide conjugates are Fc fusion peptides in which, in certain embodiments, the Fc region of the fusion peptides are the Fc region of human IgG1 or a fragment thereof. The KLK5 inhibitory peptide conjugates include an amino acid sequence of one of SEQ ID NOs: 34, 36, 38, 40, 42, 44, 46, 48, 96, 50, 52, 54, 56, 58, or 60. Pharmaceutical compositions that include the KLK5 inhibitory peptide conjugates useful for treating KLK5-related diseases are also provided.Type: ApplicationFiled: March 29, 2022Publication date: September 29, 2022Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Daisuke Nishimiya, Hidenori Yano, Hidenori Takahashi, Shinji Yamaguchi, Shiho Ofuchi